NIR-II Responsive Fe-Doped Carbon Nanoparticles for Photothermal-Enhanced Chemodynamic Synergistic Oncotherapy
ACS Applied Materials & Interfaces · 2024
DOI: 10.1021/acsami.4c09215 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2024. Verfasst von Xingyu Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Science and Technology of China, Hefei 230026, China. Hauptthemen laut MEDLINE: Carbon, Iron, Nanoparticles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Natural Science Foundation of Anhui Province.
Abstract (Originalsprache)
Phototherapy has demonstrated substantial development because in the second near-infrared (NIR-II) window it has a larger tissue penetration and fewer adverse consequences. In this work, a particular kind of NIR-II responsive Fe-doped carbon nanoparticles (FDCNs) is synthesized using a one-pot hydrothermal method for combined photothermal and chemodynamic therapy. The mesoporous nanostructure of FDCN, which has a size distribution that exceeds 225 nm, allows for effective acidification. The iron ions released from these nanoparticles can catalyze the decomposition of hydrogen peroxide (H2O2) into hydroxyl radical (•OH) for chemodynamic therapy (CDT). In addition to their CDT utility, FDCN can effectively adsorb and transform 1064 nm light into local heat, achieving a photothermal conversion efficacy (PCE) of 36.3%. This dual functionality not only allows for the direct eradication of cancer cells through photothermal therapy (PTT) but also enhances the chemodynamic reaction, creating a synergistic effect that amplifies the therapeutic outcome. The FDCN has demonstrated remarkable anticancer activity in both cellular and animal tests without incurring major systemic toxicity. This suggests that the compound has great promise for use in clinical cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Science and Technology of China, Hefei 230026, China.
- High Magnetic Field Laboratory, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, PR China.
- Hefei Cancer Hospital, Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031,…
- School of Medical Imaging, Binzhou Medical University, Yantai 264003, PR China.
- Department of Pathology and Pathophysiology, School of Basic Medicine, Anhui Medical University, Hefei, Anhui 230031, PR China.
- Nanjing Stomatological Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210008, PR China.
ORCID-Profile: Hui Wang
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Natural Science Foundation of Anhui Province
- Chinese Academy of Sciences
- High Magnetic Field Laboratory of Anhui Province
- Hefei Institutes of Physical Science Director?s Fund
- Nanjing Department of Health
Zitieren
APA
Wang, X., Song, T., Wu, X., Lin, Y., Shi, X., Qian, J., Nie, R., & Wang, H. (2024). NIR-II Responsive Fe-Doped Carbon Nanoparticles for Photothermal-Enhanced Chemodynamic Synergistic Oncotherapy. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.4c09215
Vancouver
Wang X, Song T, Wu X, Lin Y, Shi X, Qian J, et al. NIR-II Responsive Fe-Doped Carbon Nanoparticles for Photothermal-Enhanced Chemodynamic Synergistic Oncotherapy. ACS Applied Materials & Interfaces. 2024. doi:10.1021/acsami.4c09215
BibTeX
@article{Wang2024,
author = {Wang, Xingyu and Song, Tianwei and Wu, Xianli and Lin, Yefeng and Shi, Xinyi and Qian, Junchao and Nie, Rongrong and Wang, Hui},
title = {NIR-II Responsive Fe-Doped Carbon Nanoparticles for Photothermal-Enhanced Chemodynamic Synergistic Oncotherapy},
journal = {ACS Applied Materials & Interfaces},
year = {2024},
doi = {10.1021/acsami.4c09215}
}
EUVIMED